Overall, reductions ranged from approximately -16 lbs (SD = 13) to -26 lbs (SD = 20), with longer follow-up studies (up to 450 days) showing median reductions of -8.15 kg (range: -15.9 to -2.2 kg).<h4>Conclusions</h4>GLP-1 RAs are effective pharmacological adjuncts for weight loss in patients with obesity and IBD, with outcomes modulated by treatment duration and agent selection. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.